ResearchMoz

Cancer Symptoms Partnering 2007-2013

Current Partnering
Published Date » 2013-10-08
No. Of Pages » 150
 The Cancer Symptoms Partnering 2007-2013 report provides understanding and access to the cancer symptoms partnering deals and agreements entered into by the worlds leading healthcare companies. 
   
 
 
 Trends in solid tumor cancer partnering deals 
 Top solid tumor cancer deals by value 
 Deals listed by company A-Z, industry sector, stage of development, technology type 
 
 
   
 The Solid Tumor Cancer Partnering 2007-2013 provides understanding and access to the solid tumor cancer partnering deals and agreements entered into by the worlds leading healthcare companies. 
   
  This report provides details of thelatest cancer symptoms agreements announced in the healthcare sectors, covering:  
   
 
 
 Symptoms 
 Oral mucositis 
 Cancer pain...
TABLE OF CONTENT

Executive Summary
 
Chapter 1 – Introduction
 
Chapter 2 – Trends in cancer symptoms partnering
2.1. Introduction
2.2. Cancer symptoms partnering over the years
2.3. Bigpharma cancer symptoms dealmaking activity
2.4. Cancer symptoms partnering by deal type
2.5. Cancer symptoms partnering industry sector
2.6. Cancer symptoms partnering by stage of development
2.7. Cancer symptoms partnering by technology type
2.8. Disclosed financial deal terms for cancer symptoms partnering
2.8.1 Cancer symptoms headline values
2.8.2 Cancer symptoms upfront payments
2.8.3 Cancer symptoms milestone payments
2.8.4 Cancer symptoms royalty rates
 
Chapter 3 – Leading cancer symptoms deals
3.1. Introduction
3.2. Top cancer symptoms deals by value
3.3. Top cancer symptoms deals involving bigpharma
 
Chapter 4 – Dealmaking directory
4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By technology type
Analysis
Animal models
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Imaging
Industrial chemicals
In vitro models
Monoclonal antibodies
Nanotechnology
Oligonucleotide
Peptides
Personalised medicine
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Stem cells
Vaccines
 
Chapter 5 – Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
 
Appendices
 
Appendix 1 – Deal type definitions
 
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports

List of Tables

NA

List of Figures

 
Figure 1: Cancer symptoms partnering since 2007
Figure 2: Bigpharma – top 50 – Cancer symptoms deals 2007 to 2013
Figure 3: Bigpharma cancer symptoms deal frequency – 2007 to 2013
Figure 4: Cancer symptoms partnering by deal type since 2007
Figure 5: Cancer symptoms partnering by industry sector since 2007
Figure 6: Cancer symptoms partnering by stage of development since 2007
Figure 7: Cancer symptoms partnering by technology type since 2007
Figure 8: Cancer symptoms deals with a headline value
Figure 9: Cancer symptoms deals with upfront payment values
Figure 10: Cancer symptoms deals with milestone payments
Figure 11: Cancer symptoms deals with royalty rates, %
Figure 12: Top cancer symptoms deals by value since 2007
Figure 13: Top cancer symptoms deals signed by bigpharma value since 2007
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions

Upcoming Reports:

Very Large Gas Carrier Market - Global Industry Analysis, Size, Share, Trends, Analysis, Growth And Forecast 2014 - 2020
By - Transparency Market Research
Increasing LPG exports from the U.S. due to rising production of shale gas has resulted in increasing demand for very large gas carriers (VLGC). These gas carriers are used for transporting LPG and have a capacity of approximately 82,000 cubic meters. With the increasing demand of LPG from developing economies the demand for large carriers is also increasing to optimize the logistics cost and increase profitability margins. The enlarged Panama Canal is projected to open in late 2016; this would decrease the transit route between North America and Asia Pacific region. The trade between the...
Friction Products and Materials Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
Friction is the resistive force between two contacts that stop the objects from sliding. Friction occurs between all three forms of materials such as solid objects, gases and liquids. Fluid friction is the friction between liquids.   Friction materials are used to enhance the performance of vehicles, their efficiency and appearance. Major application areas of friction products and materials are light trucks, aircrafts, railways, passenger cars, commercial vehicles in addition to other industrial applications. Friction products included in the above mentioned areas are...
Hysterectomy Alternatives Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Hysterectomy is the process where complete or partial uterus is removed from the women’s body by the gynecologist. In complete uterus removal, fundus, cervix and body of the uterus are removed whereas in partial only body of the uterus is excised.Hysterectomy is performed when a women is suffering from fibroids, uterine prolapse, endometriosis, chronic pelvic pain, vaginal bleeding and cancer of uterus, ovaries and cervix. It has been observed in U.S. that 1 out of 3 women are undergoing hysterectomy annually. Hysterectomy has various issues such as hormonal imbalance,...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

A Health Tech Incubator Started by GE Healthcare
Oct 30, 2014  
For the very first time, a health tech start up campus has been established by GE Healthcare at its headquarters at Helsinki, Finland. This area already has about twenty such healthcare start ups that are working on cloud services, wireless technologies, apps, and sensors that aim at improving healthcare. The main rationale behind such a step is providing opportunities for further...
Net Earnings of DuPont Increases 52% despite Agricultural Turmoil
Oct 29, 2014  
DuPont - The Wilmington, Del-based leading chemical company faced decline of three percent sales to $7.5 billion in the quarter ending of September 30. The company’s third-quarter earnings were increased by 52 percent to $433 million albeit the slow global growth and agricultural downside.   The company witnessed the biggest drags from chemical sales with eight percent...
Appeal for Sanitization in Construction Industry through Government Regulations: CIOB Ghana
Oct 29, 2014  
Rockson Dogbegah - The Chairman of the Chartered Institute of Building Ghana commented that the construction industry needs a thorough cleaning up and assurance of proper growth. Mr. Dogbegah also said that a few factors are extremely important for a proper development in the construction industry. These include keen adherence to standards, supreme sense of professionalism, and sheer pursuance...
Facebook Hints of Rise in Expenses in 2015, Shares Drop
Oct 29, 2014  
Facebook has announced on Tuesday that it is prepping for a dramatic rise in spending in the year 2015. This warning has come combined with a projected slowdown in the company’s revenues after revenues were analyzed at the end of the third quarter of the year. The plans of such hefty spending in the next financial year by the company are indicative of stress in the investor...
China to Invest in UKs Infrastructure Industry
Oct 28, 2014  
As per industry reports, it is expected that in the year 2015, the UK infrastructure will derive benefits from 105 billion pounds of Chinese money. This will involve a host of Chinese machinery suppliers, contractors, and materials producers. The UK government will be spending about half of 225 billion pounds on its own infrastructure. The investors from China will be investing...